Virus-Antigen Conjugation via Multi-Step Chromatography Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for purifying viruses are limited in scalability and compliance with Good Manufacturing Practice (cGMP) regulations, particularly for producing highly purified viruses on a commercial scale, which is essential for vaccine development and therapeutic applications, including those for novel coronaviruses like SARS-CoV2.
Innovation Solution
A multi-set process involving filtration, ion-exchange chromatography, and multi-modal chromatography to separate and purify viruses, along with recombinant antigen production and conjugation, ensuring high purity and scalability, and compliance with cGMP regulations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If crude cell lysate methods are used for virus purification, then the process is simple and fast, but the virus purity is low due to high contamination with non-virus factors
Solution Approach 1:
The purification process is divided into multiple sequential steps: (1) initial clarification of crude lysate, (2) affinity chromatography to capture virus particles, (3) ion-exchange chromatography to remove contaminants, and (4) final filtration. This segmentation allows each step to target specific impurities while preserving virus integrity, resolving the contradiction between process simplicity and virus purity.
Solution Approach 2:
Affinity chromatography media acts as an intermediary that selectively binds to viral particles through specific ligands, enabling separation of virus from complex cell lysate. This intermediary mechanism provides high selectivity without requiring complex equipment, thus improving purity while maintaining ease of manufacture.
2Manufacturing precision
If high-speed ultracentrifugation is used for virus purification, then virus concentration is improved, but the scalability is limited and host proteins co-purify with virus samples
Solution Approach 1:
The patent replaces high-speed ultracentrifugation (mechanical system) with chromatography-based separation methods. Affinity chromatography and ion-exchange chromatography use chemical interactions rather than mechanical force to concentrate and purify viruses. This substitution enables scalable processing while achieving high virus concentration and purity without co-purification of host proteins.
Solution Approach 2:
The purification process utilizes changes in chemical parameters (pH, ionic strength, buffer composition) across different chromatography steps to selectively bind and elute viral particles. By adjusting these parameters, the process achieves high virus concentration and purity while maintaining scalability, overcoming the limitations of ultracentrifugation.
3Manufacturing precision
If density gradient ultracentrifugation is used to enhance virus purity, then the purification time is extended to 2-3 days and the quantity of virus that can be purified is limited
Solution Approach 1:
The patent extracts viral particles from complex lysates using affinity chromatography, which selectively captures viruses on charged media. This extraction step concentrates viruses quickly without requiring extended ultracentrifugation. Subsequent ion-exchange chromatography further purifies the extract, achieving high purity in a significantly reduced time frame compared to density gradient methods.
Solution Approach 2:
Affinity chromatography performs preliminary concentration and enrichment of viral particles from crude lysate before subsequent purification steps. This preliminary action reduces the volume and complexity of the sample, enabling faster and more efficient final purification without the time-consuming density gradient ultracentrifugation process.
4Ease of manufacture
If poly-ethylene glycol precipitation is used for virus purification, then the process is simple, but the product purity is poor with significant aggregation and host protein contamination
Solution Approach 1:
Chromatography media act as intermediaries that selectively interact with viral particles through specific chemical mechanisms (affinity binding, ion-exchange). These intermediaries provide selective separation based on viral surface properties, achieving high purity without the non-specific aggregation caused by poly-ethylene glycol precipitation. The process remains relatively simple while dramatically improving product purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves highly purified viruses and antigens on a commercial scale, enabling the production of effective vaccines that elicit strong immune responses and comply with regulatory standards, as demonstrated by pre-clinical studies.
Implementation Method 1
concentrating the separated and clarified virus with a filtration device
Implementation Method 2
at least one separation procedure includes ion-exchange chromatography to separate host cell contaminants from the virus
Implementation Method 3
at least one separation procedure includes a multi-modal chromatography to separate residual impurities from the virus on the basis of at least size differences between the virus and the impurities, and chemical interaction occurring between the impurities and one or more chromatography ligands
Implementation Method 4
The recombinant antigen is then expressed using the host cell's translational apparatus. After expression, the recombinant antigen can be harvested and attached to a virus via covalent bonds, through a process known as conjugation.
Data Source
AI summary
Disclosed herein are methods of forming compounds and exemplary compounds in the nature of a conjugated compound, which in some embodiments comprises an antigen and virus particle mixed in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV 2).